Cue Biopharma is trading 7% down at $25.84, extending a sharp multi-day pullback following its $50 million private placement of common stock and pre-funded warrants announced on July 10.
- The decline is primarily driven by investor concerns regarding share dilution and profit-taking following recent gains.
- Broader weakness in the biotechnology sector and a general risk-off market sentiment are adding further downward pressure to the stock.